NASDAQ · Health care

China SXT Pharmaceuticals, Inc. (SXTC)

China SXT Pharmaceuticals, Inc. reported revenue of $1.1M in fiscal 2026, down 34.6% from a year earlier. It posted a net loss of $6.2M. At March 31, 2026 it held $28.2M in cash against $644.4K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on July 1, 2026.

Price

$2.57

+0.78% on the day · September 25, 2026

52-week range $1.78 to $83,760.00

Market cap

$1.2M

Revenue (FY2026)

$1.1M

-34.6% year on year

Net margin

-545.2%

What China SXT Pharmaceuticals, Inc. does

China SXT Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SXTC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	$1.1M	-$7.1M	-$6.2M	-$9.13	n/a
2025	$1.7M	-$2.7M	-$3.3M	-$348.17	-$2.3M
2024	$1.9M	-$2.5M	-$3.1M	-$4,285.66	-$1.9M
2023	$2M	-$5.6M	-$5.9M	-$26,670.01	n/a
2022	$2.6M	-$5.2M	-$5.7M	-$165,464.45	n/a
2021	$4.8M	-$2.2M	-$2.7M	-$114,538.47	n/a

Next report expected around June 10, 2027.

Estimated from its filing rhythm: about 344 days after its last report of July 1, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where SXTC ranks in Health care

Revenue$1.1M

#566 of 646 in Health care · Bottom 12%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What China SXT Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 28, 2026
Form F-3/A filing F-3/A
August 28, 2026
Foreign issuer update 6-K
July 24, 2026
Foreign issuer update 6-K
July 24, 2026
Securities offering prospectus 424B5
July 7, 2026
Form F-3 filing F-3
July 6, 2026
Foreign issuer update 6-K
July 1, 2026
Annual report (foreign issuer) 20-F · period to March 31, 2026Revenue fell 35% to $1.1M versus the prior year; diluted EPS -$9.13 versus -$348.17.
June 1, 2026
Foreign issuer update 6-K
June 1, 2026
Securities offering prospectus 424B5
May 4, 2026
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 7, the latest on April 27, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about SXTC

What does China SXT Pharmaceuticals, Inc. do?

China SXT Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SXTC.

Is China SXT Pharmaceuticals, Inc. profitable?

No. In fiscal 2026 it reported a net loss of $6.2M on revenue of $1.1M.

How much revenue does China SXT Pharmaceuticals, Inc. make?

In fiscal 2026 China SXT Pharmaceuticals, Inc. reported revenue of $1.1M. That is 34.6% less than a year earlier.

When did China SXT Pharmaceuticals, Inc. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on July 1, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the form F-3/A filing from August 28, 2026.

Similar companies

Compare SXTC with

Compare SXTC with any company

Follow SXTC

Get an email when China SXT Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SXTC: get an email when it files

Where the numbers come from

Financial figures are the values China SXT Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.